One of the key drivers for squamous cell carcinoma (SCC) proliferation is activation of the epidermal growth factor receptor (EGFR), a known proto-oncogene. However, the mechanism of EGFR-dependent SCC proliferation remains unclear. Our previous studies indicate that epidermal growth factor (EGF)-induced SCC cell proliferation requires the SH3 domain of phospholipase C-g1 (PLC-g1), but not its catalytic activity. The SH3 domain of PLC-g1 is known to activate the short form of nuclear phosphatidylinositol 3-kinase enhancer (PIKE) that enhances the activity of nuclear class Ia phosphatidylinositol 3-kinase (PI3K) required for proliferation. However, PIKE has been described for more than a decade to be present exclusively in neuronal cells. In the present study, we found that PIKE was highly expressed in malignant human keratinocytes (SCC4 and SCC12B2) but had low expression in normal human keratinocytes. Immunohistochemical analysis showed strong nuclear staining of PIKE in human epidermal and tongue SCC specimens but little staining in the adjacent non-cancerous epithelium. Treatment of SCC4 cells with EGF-induced translocation of PLC-g1 to the nucleus and binding of PLC-g1 to the nuclear PIKE. Knockdown of PLC-g1 or PIKE blocked EGF-induced activation of class Ia PI3K and protein kinase C-z and phosphorylation of nucleolin in the nucleus as well as EGF-induced SCC cell proliferation. However, inhibition of the catalytic activity of PLC-g1 had little effect. These data suggest that PIKE has a critical role in EGF-induced SCC cell proliferation and may function as a proto-oncogene in SCC.
INTRODUCTION
The epidermal growth factor receptor (EGFR) is a proto-oncogene critical for cell proliferation, survival and migration. EGFR is overexpressed in many types of tumors, 1 --7 and has been linked with more aggressive disease and poor prognosis. 3,8 --11 Targeted control of EGFR has been proposed as an anticancer therapeutic approach.
12 --14 EGFR has intrinsic tyrosine kinase activity, upon activation by EGFR ligands, including epidermal growth factor (EGF), transforming growth factor-a, amphiregulin, heparinbinding EGF-like growth factor, betacellulin, epiregulin and epigen, 15 the tyrosine kinase is activated and phosphorylates the receptor itself and numerous downstream molecules. Activation of EGFR triggers multiple signaling pathways, including stimulation of Ras/mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K), signal transducers and activators of transcription proteins and phospholipase C-g1 (PLCg1). 16 However, the role and necessity of these pathways in the proliferative signaling of EGFR is not completely understood.
PLC-g1 is a critical molecule in growth factor-dependent signal transduction and contains two SH2, one SH3, one pleckstrin homology (PH) domain and two catalytic domains. Upon stimulation with EGFR ligands, the catalytic domain of PLC-g1 is activated by the EGFR tyrosine kinase after physical association with EGFR via its SH 2 domains. 17 The phosphorylated PLC-g1 is translocated to the plasma membrane. This phosphorylation along with binding of the N-terminal PH domain to phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ) in the plasma membrane allows phospholipase domains to hydrolyze phosphatidylinositol 4,5-bisphosphate (PIP 2 ) to inositol 1,4,5-triphosphate (IP 3 ) and diacylglycerol. 18, 19 Increased diacylglycerol activates protein kinase C-z (PKC-z) that subsequently phosphorylates the protein serine-threonine kinase Raf. Activated Raf stimulates MAPK that activates the transcriptional factors c-Jun and c-fos, eventually leading to proliferation. 20 --25 However, not all studies support the requirement of PLC-g1 catalytic activity in proliferative signaling. Fibroblasts lacking exons that encode X and both SH 2 domains of PLC-g1 display normal proliferative responses to various growth factors. 26 Others, using PLC inhibitors or antisense knockdown constructs, in normal or carcinoma cells to inhibit PLC-g1 level or its catalytic activity, demonstrate that proliferation can still occur despite blockade of PLC-g1 signaling. 27, 28 Subsequent studies showed that the SH3 domain of PLC-g1 possesses proliferative activity, 29, 30 but microinjection of the SH3 domain of PLC-g1 did not enhance EGF-induced proliferation. 31 We have recently demonstrated that PLC-g1 is overexpressed in malignant human keratinocytes (squamous cell carcinoma cells, SCC cells) and mediates SCC cell proliferation via its SH3 domain. 32, 33 The SH3 domain of PLC-g1 in the nucleus is known to act as a guaninenucleotide exchange factor for the short form of phosphoinositide 3-kinase enhancer (PIKE) that enhances the activity of nuclear class Ia PI3K required for the neuronal cell proliferation. However, PIKE has been described for more than a decade to be present exclusively in neuronal cells and is activated by nerve growth factor-induced neuronal cell proliferation. 34, 35 In the present study, we found that PIKE is highly expressed in SCC cells and mediates EGFR-dependent SCC cell proliferation. RESULTS PIKE is highly expressed in human SCC cells but at a low level in normal human keratinocytes The SH3 domain of PLC-g1 has been found to activate nuclear PIKE that activates nuclear class Ia PI3K, which in turn, triggers signaling cascades mediating neuronal cell proliferation. 34 We have demonstrated that the SH3 domain of PLC-g1 is required for EGF-induced SCC cell proliferation. 32, 33 Later, we wanted to know whether PIKE was expressed in SCC cells and interacted with PLCg1 in response to EGF in SCC cells. To address this issue, we first performed reverse transcription--PCR (RT--PCR) on RNA from human keratinocytes directly isolated from human neonatal foreskin and SCC cell lines including SCC4 derived from keratinocytes in the human tongue and SCC12B2 cells derived from keratinocytes in the facial skin. The human brain hippocampus RNA was used as a positive control for PIKE. The results showed that a fragment with a size of 2127 bp was amplified from cDNA reverse transcribed from RNA of keratinocytes, SCC4 cell and human brain hippocampus tissue (Figure 1 ). The RT--PCR product was not from the genomic DNA amplification, because no cDNA was amplified from control RNA samples incubated without reverse transcriptase (Figure 1 ). The RT--PCR was repeated three times and consistent results were obtained. We cloned this fragment and sequenced it three times in both directions and found that the nucleotide and deduced amino-acid sequence of the fragment in normal keratinocytes, SCC4 and SCC12B2 cells, were identical to the position from 56417911 to 56415784 in the PIKE locus in human chromosome 12 (12q13-15) . The N-terminal region contains proline-rich domains (PRDs) responsible for the binding of PIKE to PLC-g1 as well as p85 regulatory subunit of class Ia PI3K. These data indicate that PIKE is expressed in normal human keratinocytes and human SCC cells (SCC4 and SCC12B2).
To determine whether PIKE protein is expressed in human SCC tissue, we performed immunohistochemistry on biopsy specimens of human epidermal and oral SCC using antibodies, which recognize an epitope in the mid-region or the N-terminal portion of human PIKE. The results showed strong nuclear staining throughout the SCC tumor in 18 out of 37 (49%) patients but little staining in the adjacent non-cancerous squamous epithelium. Figure 2 shows a representative section. These results indicate that PIKE protein is highly expressed in the nucleus of human SCC.
EGF induces nuclear translocation of PLC-c1 and PLC-c1 to interact with PIKE in the nucleus of SCC4 cells To examine whether PLC-g1 translocates to the nucleus and interacts PIKE in SCC cells, SCC4 cells were treated with EGF at a concentration of 50 ng/ml or vehicle for 5 min. Cells were examined by confocal microscopy by using antibodies against PLC-g1 or PIKE. The results showed that in the absence of EGF, PLC-g1 was localized in the cytoplasm. However, in the presence of EGF, PLC-g1 was localized in the plasma membrane and nucleus. Unlike PLC-g1, PIKE is localized in the nucleus of SCC4 cells in the presence or absence of EGF. The overlay images showed a distinct colocalization (yellow) of PLC-g1 and PIKE in the nucleus of SCC4 cells in the presence of EGF (Figure 3) .
To confirm the confocal data, SCC4 cells were treated with 50 ng/ml EGF for 0 to 20 min and cells were harvested for isolation of cellular fractions. Western analysis of these fractions showed substantial increases in the levels of PLC-g1, tyrosine phosphorylated PLC-g1 (p-PLC-g1), class Ia PI3K-p85 and PKC-z in the plasma membrane isolated from cells treated with EGF for 1 min, followed by slight decrease in the levels of PLC-g1 and p-PLC-g1 in the plasma membrane 5 min after exposure to EGF. The levels of class Ia PI3K-p85 and PKC-z in the plasma membrane sustained until 20 min after EGF treatment (Figure 4) . Accordingly, levels of PLCg1, class Ia PI3K-p85 and PKC-z in the cytoplasm were decreased 1 min after EGF treatment (Figure 4) . However, the level of p-PLCg1 in the cytoplasm was increased 5 min after EGF treatment. Western analysis of the nuclear fraction showed substantial increases in the levels of PLC-g1, p-PLC-g1, class Ia PI3K-p85 and PKC-z in the nuclear lysates isolated from cells treated with EGF. Compared with the EGF-induced increase in the levels of PLC-g1, p-PLC-g1, class Ia PI3K-p85 and PKC-z in the plasma membrane fraction, the EGF-induced increase in the levels of these proteins in the nuclear fraction began at later times (5 min after EGF treatment, Figure 4 ). The highest levels of PLC-g1, p-PLC-g1 and Figure 1 . PIKE mRNA is expressed in normal human keratinocytes and human SCC cell lines. Fragments spanning from 29 to 2506 in the PIKE cDNA were reverse-transcribed and amplified by PCR from the RNA isolated from normal human brain (NHB), normal human keratinocytes (NHK) and human SCC cell lines (SCC4 and SCC12B2). The RT--PCR was performed in the presence ( þ RT) and absence (ÀRT) of reverse transcriptase. class Ia PI3K-p85 were seen at 5 min after addition of EGF, and the highest level of PKC-z appeared at a later time (10 min after addition of EGF).
Consistent with the results of confocal analysis, An 80 kDa PIKE was detected in the nuclear lysates but not in the plasma membrane or cytoplasmic lysates. EGF treatment did not affect the level of PIKE in the nucleus ( Figure 4 ). To confirm the purity of each fraction, levels of integrin 2a (plasma membrane marker), BIP (endoplasmic reticulum marker), GAPDH (cytoplasmic marker) and histone H3 (nuclear marker) were examined. The results showed that there was no detectable cross contamination in the cytoplasmic fraction (including soluble proteins and organelles), plasma membrane and nuclear fractions ( Figure 4 ). These results suggest that EGF-induces translocation of PLC-g1, PI3K-p85 and PKC-z from the cytoplasm to the plasma membrane and nucleus, as well as phosphorylation of PLC-g1.
To determine whether PLC-g1 binds to PIKE in the nucleus, SCC4 cells were treated with 50 ng/ml EGF for 10 min and cells were harvested for isolation of plasma membrane, cytoplasmic and nuclear lysates. PLC-g1 was immunoprecipitated with the antibody against PLC-g1 followed by western analysis with the antibody against the N-terminal portion of PIKE. The purity of the plasma membrane, cytoplsmic and nuclear lysates were determined using the plasma membrane marker integrin a2, reticulum marker BIP, cytoplasmic marker GAPDH and nuclear marker Histone H3. The results showed that there was no cross contamination in each cellular fraction. Immunoprecipitation assay showed that the 80-kDa short form PIKE bound to PLC-g1 in the nuclear lysates isolated from EGF-treated SCC4 cells ( Figure 5 ). In contrast, a very low level of PIKE bound to PLC-g1 was detected in the nuclear lysates of vehicle-treated SCC4 cells ( Figure 5 ). No binding between PLC-g1 and PIKE was detected in the plasma membrane and cytoplasmic lysates isolated from SCC4 cells ( Figure 5 ). These data suggest that PLC-g1 interacts with PIKE in the nucleus of SCC4 cells and this interaction is induced by EGF.
Knockdown of PIKE or PLC-c1 blocks EGF-induced activation of class Ia PI3K and PKC-f in the nucleus of SCC4 cells To determine whether PLC-g1 or PIKE has a role in mediating EGFinduced nuclear PI3K activation, SCC4 cells were treated with small interfering RNA (siRNA) for PIKE or PLC-g1 for 3 days and then with EGF for 7 min. Total cell lysates were isolated and levels of PLC-g1 and PIKE were determined to check the knockdown efficiency. b-actin was used as a loading control. In parallel experiments, nuclear and plasma membrane lysates were isolated and class Ia PI3K was immunoprecipitated by an antibody against PI3K-p85. The activity of class Ia PI3K in the precipitate was determined. The results showed that siRNA for PLC-g1 or PIKE specifically inhibited expression of PLC-g1 or PIKE ( Figure 6 ). EGF Figure 3 . EGF induces colocalization of PLC-g1 with PIKE in the nucleus of SCC4 cells. SCC4 cells cultured in serum-free medium were treated with 50 ng/ml EGF for 5 min. Cells were stained with a rabbit polyclonal antibody against PLC-g1 and a goat polyclonal antibody against PIKE, followed by the appropriate Texas Red-or flurescein-5-isothiocyanate (FITC)-conjugated secondary antibody. Fluorescent signals were detected with a confocal microscope, and red (Texas Red) and green (FITC) images (single z section) were superimposed, so that sites of staining overlap are visualized as yellow. The results are from a representative experiment that was repeated three times. Figure 4 . EGF induces translocation of PLC-g1 to the plasma membrane and nucleus. SCC4 cells cultured in serum-free medium were treated for the indicated times with 50 ng/ml EGF and harvested. Plasma membrane, cytoplasmic and nuclear lysates were isolated. Protein levels of PLC-g1, tyrosine phosphorylated PLC-g1 (p-PLC-g1), the p85 regulatory subunit of class Ia PI3K (PI3K-p85), PKC-z, integrin a2 (plasma membrane marker), BIP (cytoplasmic reticulum marker), GAPDH (cytoplasmic marker) and histone H3 (nuclear marker) were determined by western analysis. Results shown are representative of three independent experiments. stimulated activity of class Ia PI3K in both plasma membrane and nucleus of SCC4 cells transfected with control siRNA. Knockdown of PLC-g1 or PIKE blocked EGF-induced activation of class Ia PI3K in the nucleus but not in the plasma membrane ( Figure 6 ), suggesting that PLC-g1 and PIKE are required for EGF induced activation of PI3K in the nucleus. PIP 3 produced by PI3K in the nucleus has been demonstrated to activate PKC-z, implying that PKC-z is a downstream target of PI3K. 36 To determine the role of PLC-g1 and PIKE in EGF activation of PKC-z in the nucleus of SCC cells, PKC-z in the nuclear lysates or plasma membrane lysates was immunoprecipitated by an antibody against PKC-z and its activity was then determined. The results showed that EGF induced activities of PKC-z in both plasma membrane and nucleus of SCC4 cells transfected with control siRNA. EGF-induced activation of PKC-z in the nucleus was blocked by knockdown of PLC-g1 or PIKE ( Figure 6 ). In contrast, EGF-induced activation of PKC-z in the plasma membrane was blocked by knockdown of PLC-g1, but not blocked by knockdown of PIKE ( Figure 6 ). These data suggest that PLC-g1 and PIKE are required for EGF-induced PKC-z activation in the nucleus. Activation of PKC-z by EGF in the plasma membrane is presumably mediated by diacylglycerol generated by PLC-g1 hydrolysis of PIP 2 . 37 To determine whether EGF-induced activation of class Ia PI3K, and PKC-z requires catalytic activity of PLC-g1 in SCC cells, SCC4 cells were pretreated with the PLC activity inhibitor and then treated with EGF for 7 min. Cells were harvested, and nuclear and plasma membrane lysates were isolated. Following immunoprecipitation with an antibody against PI3K-p85 or PKC-z, activities of class Ia PI3K or PKC-z was determined. The results showed that inhibition of PLC activity did not affect EGF-induced activation of class Ia PI3K and PKC-z in the nucleus (Figure 6 ). In contrast, inhibition of PLC activity blocked EGF-induced activation of PKC-z but not PI3K, in the plasma membrane ( Figure 6 ). These results indicate that EGF-induced class Ia PI3K and PKC-z activation in the nucleus of SCC4 cells does not require catalytic activity of PLC-g1.
Knockdown of PIKE or PLC-c1 blocks EGF-induced nucleolin phosphorylation in SCC4 cells Nucleolin is a nuclear substrate of PKC-z 38 and involved in several aspects of RNA metabolism, including pre-rRNA synthesis, rRNA processing, ribosomal assembly and maturation. 39 Growth factors such as nerve growth factor activate nucleolin by phosphorylation at threonine sites in a PKC-z-dependent manner. 38 The activated nucleolin in the nucleus is fundamental to the survival and proliferation of cells. 40, 41 To determine whether knockdown of PLC-g1 or PIKE altered EGF-induced nucleolin phosphorylation in human SCC cells, SCC4 cells were treated with siRNA for PLC-g1 or PIKE for 3 days and then with vehicle, EGF or fetal bovine serum for 7 min. Cells were harvested and nuclear lysates were isolated. The levels of PLC-g1, PIKE, nucleolin phosphorylated on serine, total nucleolin and histone H3 were determined by western analysis. Histone H3 was used as loading control. Fetal bovine serum was used as a control for possible off-target effects of siRNA. The results showed that siRNA efficiently reduced expression of PLC-g1 or PIKE. Knockdown of PLC-g1 or PIKE blocked EGF-induced but not serum-induced threonine phosphorylation of nucleolin in SCC4 cells (Figure 7) . In contrast, the protein levels of total nucleolin and histone H3 in the nuclear lysates were not affected by EGF treatment or siRNA (Figure 7) . These results indicate that PLC-g1 and PIKE are required for EGF-induced nucleolin phosphorylation.
Knockdown of PIKE blocks EGF-induced proliferation of SCC4 cells and normal human keratinocytes
We have previously demonstrated that EGF-induced SCC4 cell proliferation requires the SH3 domain but not catalytic activity of PLC-g1. In the present study, we examined whether knockdown of PIKE blocks EGF-induced SCC cell proliferation. To address this issue, SCC4 cells were treated with siRNA for PLC-g1 or PIKE for 3 days and then with vehicle, EGF or serum for 24 h. Cells were harvested for total protein isolation. Levels of PLC-g1, PIKE and b-actin were determined by western analysis. In parallel experiments, cells were harvested and cell proliferation was assayed by [ 3 H]-thymidine incorporation. The results showed that EGFinduced SCC4 proliferation by fivefold, and knockdown of PIKE or PLC-g1 blocked EGF-induced SCC4 cell proliferation (Figure 8 ). SCC4 cells treated with fetal bovine serum were used as a control and results showed that knockdown of PLC-g1 or PIKE did not affect serum-induced proliferation (Figure 8 ). These results suggest that PLC-g1 and PIKE are required for EGF-induced SCC cell proliferation. As the 80-kDa PIKE is also expressed at low levels in normal human keratinocytes, we wanted to know whether PIKE has a role in EGF-induced keratinocyte proliferation. Our data showed that knockdown of PLC-g1 or PIKE also reduced EGFinduced but not serum-induced keratinocyte proliferation (Figure 8 ), suggesting that PIKE is required for EGF-induced keratinocyte differentiation. Lack of blocking effects of PLC-g1 or PIKE knockdown on serum-induced proliferation of SCC4 and normal keratinocytes suggest that other factors in serum regulate proliferation of these cells independent of PLC-g1 and PIKE.
DISCUSSION
Our data show for the first time that PIKE is abundantly expressed in SCC4 and SCC12B2 cell lines. We demonstrate that in SCC cells PIKE is localized in the nucleus where it binds to PLC-g1 in response to EGF and required for EGF-induced cell proliferation. Our previous studies have indicated that PLC-g1 is required for EGF-induced SCC cell proliferation, 32 and the proliferative role of PLC-g1 in SCC cells is dependent on its SH3 domain but independent of its lipase activity. 32, 33 In response to EGF, PLC-g1 is translocated not only to the plasma membrane but also to the nucleus. 32 The role of PLC-g1 in the nucleus was first described in neuronal cells by Ye et al. 34 PLC-g1 in the nucleus acts as a guanine-nucleotide exchange factor, through its SH 3 domain in a lipase-independent manner, to facilitate GTP binding to and GDP dissociation from nuclear PIKE GTPase. Binding of GTP enables PIKE to interact with nuclear class Ia PI3K and enhance activity Figure 5 . EGF induces PLC-g1 to form a complex with PIKE in the nucleus. SCC4 cells cultured in serum-free medium were treated with EGF ( þ ) or vehicle (À) for 10 min. Cells were harvested. Plasma membrane, cytoplasmic and nuclear lysates were isolated. The complex formation of PLC-g1 with PIKE was analyzed by immunoprecipitation with an antibody against PLC-g1 followed by western analysis with an antibody against the N-terminus of PIKE. The protein levels of histone H3 (nuclear marker), BIP (cytoplasmic reticulum marker), GAPDH (cytoplasmic marker) and integrin a2 (plasma membrane marker) were determined by western analysis to check the purity of the plasma membrane, cytoplasmic and nuclear lysates. Results shown are representative of three independent experiments.
PI3K
. 34 Nerve growth factor stimulates PLC-g1 translocation to the nucleus, where it binds to the third PRD of PIKE and regulates the effect of PIKE on class Ia PI3K. 34 However, PIKE was thought to be exclusively expressed in the brain. 35 Our studies clearly show that PIKE is present in keratinocytes, SCC4 and SCC12B2 cell lines. The expression of PIKE in human SCC is remarkably higher than that in adjacent non-cancerous tissue. These results are similar to those of EGFR and PLC-g1 overexpression in SCC. 1, 2, 32 Given the fact that PIKE has a critical role in EGF-induced SCC cell proliferation, PIKE is likely to function as a proto-oncogene in SCC. PIKE, similar to many known proto-oncogenes, is expressed at a very low level in normal human keratinocytes but is required for EGF-induced keratinocyte proliferation.
Three alternatively spliced forms of PIKE have been discovered to date. The short form of PIKE (80 kDa) and the long form of PIKE (120 kDa) contain three PRDs, a GTPase domain and a PH domain. The short form of PIKE is exclusively in the nucleus and activated by nuclear PLC-g1. The long form of PIKE resides in both nuclear and cytosolic compartments. In addition to the PRDs, GTPase and PH domains, the long form of PIKE contains an ADP riobosylation-GAP (ArfGAP) domain and two ankyrin repeats. The first PRD binds to the p85 subunit of class Ia PI3K and 4.1N. 35 The second PRD binds to the p110 subunit of class Ia PI3K. 35 The interaction between PIKE and class Ia PI3K is GTP dependent. 35 The third PRD binds to the SH3 domain of PLC-g1. 34 Another PIKE isoform, PIKEactivating Akt (PIKE-A), contains the GTPase, PH, ArfGAP and two ankyrin repeats domains but lacks the N-terminal PRDs. Like the long form of PIKE, PIKE-A is both cytosolic and nuclear. PIKE-A binds to Akt and stimulates its activity in a GTP-dependent manner, inhibiting apoptosis and promoting human cancer cell invasion. 42 Among these isoforms, the short and long forms of PIKE have been found in neuronal tissue. 35, 43 PIKE-A has been found in various tissues and acts as a proto-oncogene. 43 PIKE-A is the only isoform lacking the N-terminal PRDs. 42 In the present Figure 6 . EGF-induced nuclear class Ia PI3K and PKC-z activation is blocked by knockdown of PLC-g1 or PIKE but not by inhibition of PLC activity, in SCC4 cells. SCC4 cells were transfected with siRNA for PLC-g1 or PIKE (a) or treated with PLC inhibitor U73122 or the vehicle (b) and then treated with EGF (50 ng/ml, þ ) or vehicle (À) for 7 min. Cells were harvested. Nuclear and plasma membrane lysates were isolated. Protein levels of PLC-g1, PIKE and b-actin in the total cell lysates were determined by western analysis. In parallel experiments, protein of PLC-g1 in the total lysates or protein of class Ia PI3K or PKC-z in the nuclear or plasma membrane lysates was immunoprecipitated with an antibody against PLC-g1, class Ia PI3K-p85 or PKC-z. Activities of PLC-g1, class Ia PI3K or PKC-z in the nuclear and cytoplasmic lysates were study, RT--PCR and sequence analysis indicated the presence of the PIKE transcript containing N-terminal PRDs in SCC cells. Antibody against the N-terminus of PIKE revealed expression of PIKE in the nucleus of human SCC. Western analysis suggested presence of the 80-kDa PIKE protein and interaction between PIKE and PLC-g1 in SCC cells in response to EGF. These results suggest presence of the short form of PIKE in the nucleus of SCC cells. By using the antibody against the N-terminus of PIKE, we did not detect expression of the long form of PIKE in SCC4 cells. Because PIKE-A lacks the N-terminal sequence but possesses the C-terminal sequence, we used the antibody against the C-terminal sequence to examine the SCC tissue and SCC cell lines (SCC4 and SCC12B2), and we did not detect expression of PIKE-A in any of those human SCC tumor specimens or SCC cell lines (data not shown). Thus, it appears that the short form of PIKE is the only isoform expressed in SCC. PLC-g1 is known to be phosphorylated at tyrosine sites by EGFR in the plasma membrane. 37 In the present study, we demonstrate that EGF induces decreases in the levels p-PLC-g1 in the cytoplasm and increases in the levels of p-PLC-g1 in the plasma membrane and nucleus, suggesting that EGF induces translocation p-PLC-g1 from the cytoplasm to the plasma membrane and nucleus. The decreases in the levels of p-PLC-g1 in the nucleus suggest that the PLC-g1 dephosphorylation may occur in the nucleus. However, it is unclear whether phosphorylation of PLC-g1 required for its nuclear translocation. Further investigation is required to address this issue. We have previously shown that EGF-induces translocation of PLC-g1 to the nucleus of SCC4 cells. In the present study, our data show that PI3K and PKC-z, like PLC-g1, reside mainly in the cytoplasm of quiescent SCC4 cells. Upon EGF stimulation, the levels of PI3K and PKC-z are increased in the plasma membrane and nucleus but decreased in the cytoplasm after EGF stimulation. These data suggest that EGF induces translocation of PI3K and PKC-z from the cytoplasm to the plasma membrane and nucleus. The mechanism by which PI3K and PKC-z translocate to the nucleus at this point is unclear. The nuclear membranes certainly contain abundant quantities of the substrate for PI3K. Some work suggest that PIP 3 generated by PI3K in the nucleus is likely to act as a driving force for the nuclear translocation of PKC-z 44 --46 and activate PKC-z, 36 which in turns activates nucleolin by phosphorylation. 38 Activated nucleolin is involved in various aspects of DNA and RNA metabolism 39 essential for cell proliferation. 40, 41, 47, 48 We here demonstrate that in SCC cells EGF-induces activation of PI3K and PKC-z as well as nucleolin phosphorylation in the nucleus, and these processes require PLC-g1 and PIKE.
Our results show that the levels of PLC-g1, PI3K and PKC-z in the nucleus are increased and then decreased but do not fall below the baseline levels in response to EGF, suggesting that there is an increase followed by a decrease in the translocation of these proteins from the cytoplasm to the nucleus. However, the changes in the levels of PLC-g1, p-PLC-g1, Ia PI3K-p85 and PKC-z in the cytoplasm did not negatively correlate well with that of changes in the levels of these proteins in the nucleus. This probably reflects small amounts of these proteins translocated from the cytoplasm to the nucleus.
Taken together, our studies indicate that PIKE is highly expressed in human SCC and has a critical role in EGF-induced SCC cell proliferation. The present studies, for the first time, begin to address potentially key aspects of the oncogenic role of PIKE in SCC. Future studies are required to determine whether PIKE is sufficient to promote SCC ontogenesis, and whether this pathway interacts with other EGFR pathways.
MATERIALS AND METHODS

Polyclonal antibody against PIKE
The customized rabbit polyclonal antibody against human PIKE was made by Covance Inc. (Covance Inc., Princeton, NJ, USA). The antibody was generated using a peptide that contains the region at the N-terminus of the human PIKE protein. The antibody was characterized using immunocytochemistry and western analysis using protein lysates isolated from human brain.
Immunohistochemistry
Human SCC tissue was collected at the Second Xiangya Hospital of Central South University in China from 37 patients undergoing primary resection of SCC of the oral mucosa or skin. All these patients were diagnosed with SCC. The tissue was fixed in 4% paraformaldehyde at 4 1C overnight and dehydrated. Paraffin-embedded tissue was cut into 5 mm sections. After deparaffinization and rehydration, the sections were stained with polyclonal rabbit antibody against the mid-region of human PIKE at a dilution of 1:100 (Millipore, Billerica, MA, USA) or customized polyclonal antibody against the N-terminal region of human PIKE at a dilution of 1:1000 (Covance Inc.) using Rabbit ImmunoCruz Staining System (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and then counterstained with hematoxylin.
Cell culture
Human SCC cell lines including SCC4 (tongue SCC) and SCC 12B2 (epidermal SCC) obtained from ATCC were grown in SCC medium composed of a 1:1 mixture of Ham's F12 and Dulbecco's modified Eagle's medium with 10% fetal bovine serum. Cells were switched to serum-free medium for 24 h before treatment with EGF. Human keratinocytes were isolated from neonatal human foreskins and cultured in serum-free medium as described previously. 49 --52 Cells were viable under the serumfree condition.
RNA isolation, RT--PCR and sequencing
Total RNA was isolated from normal human keratinocytes and SCC4 and SCC12B2 cells using Qiagen RNeasy kit according to the manufacturer's instructions (Qiagen, Valencia, CA, USA). RNA (1 mg) was reverse transcribed to cDNA using reverse transcriptase. The cDNA was used as templates for subsequent PCR amplification using primers spanning the N-terminal region. The cDNA was sequenced completely in both strands. . To knockdown PLC-g1 or PIKE, cultured SCC4 cells or normal human keratinocytes at 5% confluency were transfected with siRNA for PLC-g1, PIKE or negative control at a concentration of 100 nM in accordance with manufacturer's recommendations using TransIT-siQUEST transfection reagent (Mirus, PanVera Corp., Madison, WI, USA) at a dilution of 1:750 according to the manufacturer's protocol.
Cell lysate preparation
Total cell lysates were extracted with 1% NP-40. The nuclear and cytoplasmic lysates were extracted using the NE-PER kit (Thermo Fisher Scientific, Rockford, IL, USA). The plasma membrane lysates were extracted using the Mem-PER kit (Thermo Fisher Scientific). This extraction kits can efficiently separate the plasma membrane or nuclear fraction from the cytoplasmic fraction, and the protein isolated can be used in the co-immunoprecipitation and western analysis, as well as enzymatic assays. 32,50 --52 Western analysis and co-immunoprecipitation Equal amounts of protein were immunoprecipitated and/or electrophoresed, blotted and probed using appropriate antibodies as previously described.
32,50 --52.
These antibodies include polyclonal antibodies against human PLC-g1 (Santa Cruz), PIKE (Customized), and PKC-z (Santa Cruz). Western analysis of markers of cytoplasm (soluble protein GAPDH and endoplasmic reticulum protein BIP), plasma membrane (integrin 2a) and the nucleus (histone H3) were included to check the purity of the plasma membrane, cytoplasmic and nuclear fractions.
PLC-c1 activity assay PLC-g1 in the total cell lysates was immunoprecipitated using polyclonal antibody against PLC-g1 (Santa Cruz) for 1 h at 4 1C and then 20 ml UltraLink Immobilized Protein G for 1 h at 4 1C. After a series of washes, the conjugated beads were then assayed for PLC-g1 activity by measuring accumulation of IP 3 according to the experimental procedure described previously. 50 --52 PI3K activity assay
The activity of class Ia PI3K was determined by the PI3K-ELISA kit (Echelon Research Laboratories, Salt Lake City, UT, USA) that detects the formation of PIP 3 from PIP 2 . Briefly, class Ia PI3K in the nuclear or plasma membrane extracts was immunoprecipitated using polyclonal antibody against the regulatory subunit of class Ia PI3K (PI3K-p85, Upstate, Charlottesville, VA, USA) for 1 h at 4 1C and then 20 ml UltraLink Immobilized Protein G for 1 h at 4 1C. After a series of washes, the conjugated beads were then assayed for class Ia PI3K activity according to the manufacturer protocol. The activity of class Ia PI3K was normalized to the protein content in the immunoprecipitate.
PKC-f activity assay
The activity of nuclear and plasma membrane PKC-z was determined by the PKC-z activity assay kit (Assay Designs Inc., Ann Arbor, MI, USA). Briefly, PKC-z in the nuclear or plasma membrane extracts was immunoprecipitated using polyclonal antibody against PKC-z (Santa Cruz) for 1 h at 4 1C and then 20 ml UltraLink Immobilized Protein G for 1 h at 4 1C. After a series of washes, the conjugated beads were then assayed for PKC-z activity according to the manufacturer protocol. The activity of PKC-z was normalized to the protein content in the immunoprecipitate.
Proliferation assay
Cell proliferation was assayed by [ 3 H]-thymidine incorporation. Briefly, SCC4 cells were seeded in six-well plates at 5% confluence and grown in SCC medium with 10% fetal calf serum. Normal human keratinocytes were seeded in six-well plates at 5% confluence and grown in serum-free medium (medium 154CF with human keratinocyte growth supplement; Cascade Biologics, Portland, OR, USA) containing 0.07 mM calcium. After 24 h of incubation in 5% CO 2 at 37 1C, cells were cultured in serum-free medium for 24 h. EGF was added and cells were incubated for 24 h. During the last 8 h of incubation, 1 mCi per well of [ 3 H]-thymidine was added. Cells
